CLINICAL TRIALS PROFILE FOR TALAPORFIN

Clinical Trials for Talaporfin

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00068068 ↗	Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases	Completed	Light Sciences LLC	Phase 2	The purpose of this study is to determine whether the Litx platform is safe and effective in the treatment of liver metastasis arising from colorectal cancer. Litx is a next-generation photodynamic therapy platform in which the drug, talaporfin sodium (LS11), is activated by light from the light-emitting diode (LED)-based light infusion device, inserted directly into the tumor through the skin prior to treatment.
NCT00083785 ↗	Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases	Completed	Light Sciences LLC	Phase 2	The purpose of this study is to determine whether the Litx™ system is safe and effective in combination with chemotherapy in the treatment of liver metastasis arising from colorectal cancer. Litx™ is a next-generation photodynamic therapy platform in which the drug, talaporfin sodium (LS11), is activated by light from the light-emitting diode (LED)-based light infusion device, inserted directly into the tumor through the skin prior to treatment.
NCT00102115 ↗	Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease	Terminated	Light Sciences LLC	Phase 1	The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).
NCT00122876 ↗	Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)	Completed	Light Sciences Oncology	Phase 1/Phase 2	The purpose of this study is to determine whether the Litx™ treatment is safe and effective in treating inoperable hepatocellular carcinoma (HCC). Litx™ is an integrated treatment system comprising an intravenously administered photosensitizing agent, Talaporfin Sodium (LS11), that is activated by non-coherent light generated inside the tumor by an implanted light emitting diode (LED) array light source.
NCT00355355 ↗	A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)	Completed	Light Sciences Oncology	Phase 3	The purpose of the study is to assess the survival of patients treated with Litx™ versus standard of care therapies in the treatment of unresectable hepatocellular carcinoma (HCC), and to demonstrate the safety of Litx™ therapy. Litx™ consists of a light-activated drug, talaporfin sodium (LS11, Light Sciences Oncology, Bellevue, Washington), and a light generating device, composed of light-emitting diodes (LEDs), that is energized by a power controller and percutaneously placed in the target tissue inside the body.
NCT00409214 ↗	Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma	Completed	Light Sciences Oncology	Phase 2	The pupose of this study is to demonstrate the safety of the Litx™ therapy and confirm the zone of tumor destruction with escalated light doses following intraoperative treatment of primary or recurrent glioma.

Clinical Trial Conditions for Talaporfin

Condition Name

Condition Name for
Intervention	Trials
Liver Neoplasms	4
Benign Prostatic Hyperplasia	3
Neoplasm Metastasis	3
Colorectal Neoplasms	3

Condition MeSH

Condition MeSH for
Intervention	Trials
Liver Neoplasms	5
Colorectal Neoplasms	3
Prostatic Hyperplasia	3
Neoplasms, Second Primary	3

Clinical Trial Locations for Talaporfin

Trials by Country

Trials by Country for
Location	Trials
United States	35
India	4
Hong Kong	3
Serbia	3
Poland	2

Trials by US State

Trials by US State for
Location	Trials
Washington	4
Pennsylvania	3
California	3
Texas	3
Alaska	2

Clinical Trial Progress for Talaporfin

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	5
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	10
Terminated	2

Clinical Trial Sponsors for Talaporfin

Sponsor Name

Sponsor Name for
Sponsor	Trials
Light Sciences Oncology	7
Light Sciences LLC	3
United States Department of Defense	1

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	11
Other	3
U.S. Fed	1